Biocity Biopharmaceutics Co., Ltd.
Registry sponsor category
Industry
- Other names
- Biocity Biopharmaceutics Co., Ltd.
- Company name
- Biocity Biopharmaceutics Co., Ltd.
- Organisation type
- Industry
- Registry sponsor category
- Industry
- Publicly traded (proxy)
- No
- Listing at source
- Listed
Related records
Trials (12)
- A Phase I Study of BC3402 as a Single Agent in Patients With MDS and CMML
- A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria
- A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer
- A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC2027 in Patients With Advanced Solid Malignancies
- BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
- BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma
- dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation
- SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer
- SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
- Study of BC3195 Monotherapy in Patients With Advanced Solid Tumors
- Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML